# Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors

> **NCT07404176** · PHASE2 · RECRUITING · sponsor: **Tata Memorial Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Neuroendocrine Neoplasms (Tumours)
- Neuroendocrine Tumors
- Metastatic Neuroendocrine Tumors

## Interventions

- **DRUG:** Terbium 161

## Key facts

- **NCT ID:** NCT07404176
- **Lead sponsor:** Tata Memorial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2028-02-28
- **Final completion:** 2029-02-28
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07404176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07404176, "Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07404176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*